|
| | HR0163 | | LRB103 31459 MST 59200 r |
|
|
1 | | HOUSE RESOLUTION
|
2 | | WHEREAS, Respiratory Syncytial Virus disease (RSV) is a |
3 | | highly transmissible, seasonal virus that can have severe and |
4 | | unpredictable outcomes for infants, including hospitalization; |
5 | | and
|
6 | | WHEREAS, Nearly all children will be infected with RSV by |
7 | | age two, and most infants requiring hospitalization were |
8 | | previously healthy and born at term; and
|
9 | | WHEREAS, RSV is the leading cause of hospitalization among |
10 | | infants in the U.S.; and
|
11 | | WHEREAS, RSV is the most common cause of bronchiolitis |
12 | | (inflammation of the small airways in the lung) and pneumonia |
13 | | (infection of the lungs) in children younger than one year of |
14 | | age in the U.S.; and |
15 | | WHEREAS, The current RSV season has resulted in |
16 | | significant morbidity and increased mortality; and |
17 | | WHEREAS, In the U.S., RSV infections typically occur |
18 | | during late fall, winter, and early spring, which means urgent |
19 | | preparation is needed; and |
|
| | HR0163 | - 2 - | LRB103 31459 MST 59200 r |
|
|
1 | | WHEREAS, Monoclonal antibodies show promise in |
2 | | preventative protection against RSV; and |
3 | | WHEREAS, RSV disproportionally affects infants with |
4 | | Medicaid coverage, Native Americans, and Alaskan Natives; and
|
5 | | WHEREAS, The Vaccines For Children (VFC) program is a |
6 | | federally-funded program that provides vaccines at no cost to |
7 | | children who might not otherwise be vaccinated because of |
8 | | inability to pay; and
|
9 | | WHEREAS, VFC coverage is critical to ensure equity and |
10 | | access for all infants in order to have the greatest impact on |
11 | | disease burden; therefore, be it
|
12 | | RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE ONE |
13 | | HUNDRED THIRD GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that |
14 | | we urge the Centers for Disease Control and Prevention to |
15 | | include new RSV immunization technologies (including vaccines |
16 | | and monoclonal antibodies), within the federal VFC program if |
17 | | the Advisory Committee on Immunization Practices of the |
18 | | Centers for Disease Control and Prevention issues |
19 | | administrative recommendations that are subsequently approved |
20 | | by the Director of the Centers for Disease Control and |
21 | | Prevention; and be it further
|